報價延遲最少15分鐘:2024/12/24 13:41 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.97 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.36/-0.51
|
|
企業價值
70.10M
|
| 資產負債 |
|
每股賬面淨值
0.08
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/12/24 13:41 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatment. The other projects in the company's pipeline include, Bracelet-1 for treatment of Breast Cancer, Goblet cohort-1, Goblet cohort-5 for treatment of Gastro-Intestinal Cancer among others. |